Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Oncternal Therapeutics

10/03/2022 22:06

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 16 cents​​ per share for the quarter ended in
December. The mean expectation of five analysts for the quarter
was for a loss of 25 cents per share.
    * Revenue fell 65% to $556.00 thousand from a year ago; 
analysts
expected $1.52 million. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Oncternal Therapeutics Inc shares had fallen by 23.8% this
quarter.
    * The company reported a quarterly loss of $8.07 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $16.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 10 at 10:06 p.m.  ​All
figures in US dollars unless otherwise stated